All In Biotech

NDA 018013 · Specgx LLC

Pamelor

Nortriptyline Hydrochloride · Oral

Discontinued

Last checked: Nov 19, 2026Latest source record: Apr 9, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1977

Aug 1, 1977

Approved uses

3

Original approval plus efficacy supplements

Registered trials

58

8 Phase 3, 1 recruiting

FAERS reports

5,962

4,261 serious, 757 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and...

What it is approved for

From the label in effect Dec 4, 2024.

INDICATIONS AND USAGE Pamelor™ (nortriptyline HCl) is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 18, 1982 Supplement 2 · Efficacy
  • Jun 29, 1978 Supplement 1 · Efficacy
  • Aug 1, 1977 Original approval · Type 5 - New Formulation or New Manufacturer Other Important Information from FDA
4 products under this application
  • PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, ORAL · Discontinued · TE AB
  • PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE, ORAL · Discontinued · TE AB
  • PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 50MG BASE · CAPSULE, ORAL · Discontinued · TE AB
  • PAMELOR · NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE · CAPSULE, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nortriptyline" as an intervention, any sponsor and status, largest first.

All 58 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective884
  • off label use838
  • pain742
  • headache733
  • fatigue633
  • nausea605
  • hyperhidrosis594
  • hypersensitivity505
  • drug hypersensitivity448
  • constipation441
  • hypertension439
  • rheumatoid arthritis423

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200483
200583
200673
200780
200870
200981
2010196
2011197
2012177
2013121
2014155
2015193
2016262
2017236
2018271
2019408
2020422
2021414
2022418
2023453
2024582
2025543
2026444

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pamelor (Nortriptyline HCl)

2024 spending

$1.0M

Beneficiaries

70

295 claims

Per beneficiary

$14,524

$38.90 per unit

View as table
YearSpending
2020$1,871,415
2021$1,772,011
2022$1,705,339
2023$1,518,564
2024$1,016,661

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 587 on PubMed

Sponsor: Specgx LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.